---
title: 'Bioanalyst at Immunome, Inc.'
canonical: 'https://feeny.ai/job/bioanalyst-immunome-inc-bothell-1vp2xjay98r9'
type: 'job'
last_seen: '2026-10-17'
---

# Bioanalyst at Immunome, Inc.

- **Company:** Immunome, Inc.
- **Location:** Bothell, WA
- **Compensation:** $120k–$142k
- **Posted:** 2026-09-24
- **Last confirmed live:** 2026-10-17
- **Apply:** https://job-boards.greenhouse.io/immunomeinc/jobs/5431985008

## Job description

Company Overview

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been accepted by the U.S. FDA; IM-1021, a clinical-stage ROR1 ADC; IM-1617, a clinical-stage solid tumor ADC; and IM-3050, a clinical-stage FAP-targeted radioligand therapy. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets.

Position Overview

The Bioanalyst will be responsible for developing and implementing bioanalytical assays to support clinical stage bioanalysis for candidate drugs. In this role, they will participate in the design, development, and implementation of the bioanalytical strategy for multiple oncology programs. This role reports to the Associate Director, Bioanalytical.

## Responsibilities

- Develop and implement bioanalytical assays for compounds in clinical development. This includes scientific and technical oversight of CROs performing the bioanalytical lab work as well as ensuring scientific and regulatory compliance.
- Act as the primary contact and maintain working relationships with external vendors to facilitate execution of bioanalytical strategies.
- Actively partner with other functions and departments to ensure that programs are progressed seamlessly through the development process; ensure bioanalytical subject matter expertise is represented in cross-functional project teams.
- Author relevant sections of clinical study protocols, analysis plans, reports and regulatory submissions (such as IBs, CTDs, INDs, BLAs).

## Qualifications

- A minimum of 5 years' experience in pharmaceutical/biotechnology industry in a regulated bioanalytical environment, preferably with multiple modalities, including small molecules, large molecules, and ADCs.
- A minimum of 3 years of experience managing relationships with global bioanalytical vendors (CRO’s) is required.
- Familiarity with current global bioanalytical regulatory guidance.
- Regulated lab experience (GLP, GCLP, ICH M10).
- History of hands-on bench-level experience with method development, validation, and troubleshooting is required. (Ligand-binding and/or LC-MS/MS).

Knowledge and Skills

- Demonstrated experience supporting clinical and regulatory development of bioanalytical requirements, GxP regulations, with excellent working knowledge of the regulatory process.
- Excellent problem-solving skills and ability and desire to oversee multiple projects simultaneously in a fast-paced environment.
- Demonstrated experience in the development and execution of bioanalytical plans to support clinical development.
- Outstanding interpersonal and communication skills (written and oral) with ability to communicate complex information succinctly.
- Experience authoring relevant sections of global regulatory submissions and interacting with global health authorities.
- Ability to drive collaboration, achieve results, influence, and resolve conflicts across internal and external project teams.

Washington State Pay Range $120,200—$141,960 USD

E/E/O

Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.

E-Verify

Immunome, Inc. is a participant in E-Verify. Please review the following notices: [E-Verify Participation Poster](https://immunome.box.com/s/bopxukipfidxjscs4bjxt75f90bvpppk) | https://immunome.box.com/s/r51g9subw1wqni9xkutbl6up635sjr8e | https://immunome.box.com/s/r3ekbimwh988my9vzl76tnlbg60zvh9u.

## About Immunome, Inc.

## Company Overview
- **One-liner**: Immunome is a clinical-stage oncology company developing first-in-class and best-in-class targeted cancer therapies, with a primary focus on antibody-drug conjugates (ADCs).
- **Entity Type**: Public (Nasdaq: IMNM)
- **Headquarters**: Bothell, Washington, United States
- **Founded**: The company was formed through a merger of Morphimmune and Immunome in October 2023.
- **Founders**: The company is led by Clay Siegall, Ph.D. (Chairman, CEO, and President), who co-founded Seagen. The original Immunome entity was founded earlier, but the current company structure dates to the 2023 merger.

## Core Business
- Primary industry/industries: Biotechnology, Oncology, Drug Discovery & Development
- Target customers: Patients with cancer, healthcare providers, and clinical trial sites. The company is a B2B/B2C entity in the healthcare and life sciences space.
- Mission or purpose statement: "Our mission is to improve outcomes for cancer patients by advancing and expanding a portfolio of first-in-class and best-in-class therapeutic candidates." [immunome.com](https://immunome.com/)

## Products & Services
- **Varegacestat (formerly AL102)**: A late-clinical stage gamma secretase inhibitor for the treatment of desmoid tumors. The company submitted a New Drug Application (NDA) to the U.S. FDA in April 2026. [investors.immunome.com](https://investors.immunome.com/)
- **IM-1021**: A ROR1-targeted antibody-drug conjugate (ADC) currently in a Phase 1 trial.
- **IM-3050**: A FAP-targeted radioligand which received IND clearance in Q1 2025.
- **Preclinical ADC Pipeline (IM-1617, IM-1340, IM-1335)**: ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 had its first patient dosed in a Phase 1 trial in June 2026. [investors.immunome.com](https://investors.immunome.com/)

## Market Standing
- **Valuation/Market Cap**: Not publicly available in the search results. As a public company, this fluctuates. (Check recent filings for current data).
- **Key Metric**: The company is pre-revenue (clinical-stage) and has raised significant capital. Since the 2023 merger, CEO Clay Siegall has raised $355 million in equity financings. [immunome.com](https://immunome.com/about/)
- **Notable Investors/Partners**: The company is publicly traded. Key leadership previously worked at Seagen (acquired by Pfizer for $43 billion).
- **Growth Signals**: The company is rapidly advancing its pipeline. Key milestones include the NDA submission for varegacestat, first patient dosed for IM-1617, and positive Phase 3 data presented at ASCO 2026. The company currently lists 32 open positions on its careers page, indicating strong hiring momentum. [job-boards.greenhouse.io](http://job-boards.greenhouse.io/immunomeinc)

## Competitive Advantages
- **World-Class Leadership**: The executive team, led by Seagen co-founder Clay Siegall, has deep experience in designing, developing, and commercializing blockbuster ADCs (ADCETRIS, PADCEV, TIVDAK, TUKYSA). [immunome.com](https://immunome.com/about/)
- **Proprietary ADC Platform**: A systematic, data-driven process for optimizing antibodies, linkers, and payloads to create differentiated ADCs. [immunome.com](https://immunome.com/)
- **Near-Term Catalyst**: The NDA submission for varegacestat provides a potential near-term commercial opportunity.
- **Strong Financial Backing**: Raised $355M in equity since the merger, providing a solid runway for pipeline advancement.

## Strategic Focus
- **Advancing the Pipeline**: The primary focus is on executing clinical trials for varegacestat (Phase 3), IM-1021 (Phase 1), and IM-3050 (Phase 1), and advancing preclinical ADCs into the clinic.
- **Regulatory Filing**: Successfully navigating the FDA NDA submission and potential approval for varegacestat.
- **Discovery & Expansion**: Using their ADC discovery platform to generate new candidates and identify and acquire targeted oncology assets to expand the portfolio. [immunome.com](https://immunome.com/about/)

## Why Work Here
- **Mission-Driven**: The work directly impacts the lives of cancer patients, with a stated goal of developing transformative therapies. [immunome.com](https://immunome.com/about/)
- **High-Impact Team**: Opportunity to work with "some of the brightest and most experienced minds in ADC development," including leaders who have brought multiple drugs to market. [immunome.com](https://immunome.com/careers/)
- **Growth Stage**: With 32 open roles, the company is in a rapid growth phase, offering significant career advancement opportunities. [job-boards.greenhouse.io](http://job-boards.greenhouse.io/immunomeinc)
- **Comprehensive Benefits**: Includes 100% company-paid medical premiums for employees, a 401(k) with employer match, paid parental leave, and a week-long winter break. [immunome.com](https://immunome.com/careers/)
- **Location & Culture**: Based in Bothell, WA. The company describes a culture of "innovative, collaborative environment where employees are empowered to do their best work." [immunome.com](https://immunome.com/careers/)

## Sources
1. [Immunome Official Website](https://immunome.com/)
2. [Immunome About Page](https://immunome.com/about/)
3. [Immunome Investor Relations](https://investors.immunome.com/)
4. [Immunome Careers Page](https://immunome.com/careers/)
5. [Immunome Jobs on Greenhouse](http://job-boards.greenhouse.io/immunomeinc)

## Other roles at Immunome, Inc.

- [Senior Director, Commercial Accounting](https://feeny.ai/job/senior-director-commercial-accounting-immunome-inc-bothell-b6t8y9rjmfjz) — Bothell, WA
- [Senior Manager, IT Service Desk](https://feeny.ai/job/senior-manager-it-service-desk-immunome-inc-bothell-hbryvrpksf4x) — Bothell, WA
- [Principal Statistical Programmer](https://feeny.ai/job/principal-statistical-programmer-immunome-inc-bothell-wa5ztbq83wm4) — Bothell, WA
- [Senior Manager, Statistical Programming](https://feeny.ai/job/senior-manager-statistical-programming-immunome-inc-bothell-wp8jzns2hctg) — Bothell, WA
- [Scientist II, Clinical Pharmacology & Pharmacometrics](https://feeny.ai/job/scientist-ii-clinical-pharmacology-pharmacometrics-immunome-inc-bothell-ecjqqk06j825) — Bothell, WA
- [Principal Scientist, Clinical Pharmacology & Pharmacometrics](https://feeny.ai/job/principal-scientist-clinical-pharmacology-pharmacometrics-immunome-inc-bothell-4223cdm2tesv) — Bothell, WA
- [Senior Director, Development Quality Assurance](https://feeny.ai/job/senior-director-development-quality-assurance-immunome-inc-bothell-jhn4eb9nzy7g) — Bothell, WA
- [Senior In-House Clinical Research Associate](https://feeny.ai/job/senior-in-house-clinical-research-associate-immunome-inc-bothell-xd757hs9sz89) — Bothell, WA
- [Senior / Principal Scientist, Formulation and Drug Product Development](https://feeny.ai/job/senior-principal-scientist-formulation-and-drug-product-development-immunome-thyg2s4vvxng) — Bothell, WA
- [Senior Manager, Clinical Project Management (Project Delivery)](https://feeny.ai/job/senior-manager-clinical-project-management-project-delivery-immunome-inc-bothell-4qv8cbmwxyhp) — Bothell, WA